Enabling CF Therapeutic Development
|
|
- Bernadette Stone
- 5 years ago
- Views:
Transcription
1 Enabling CF Therapeutic Development PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs No Disclosures
2 Cystic Fibrosis In 1955 In 1955 most children with CF did not live long enough to go to school
3 Cystic Fibrosis Today Median survival is almost 40 years of age One half of all patients are adults Eight CF therapies are now FDA approved One new CF therapy treats the basic defect and more are in the pipeline
4 How did this happen?
5 CF Care Was Organized Peer-reviewed centers Multidisciplinary teams Web-based registry collects relevant data Published evidencebased guidelines Robust quality improvement program Care Center Network Established in 1960
6 CF Foundation Patient Registry Proved Invaluable Epidemiologic research: informs disease progression and best practice ( > 100 publications) Informs study design Query tool at sites to screen for trial eligibility Matched control group for open-label studies of investigational agents Tool for phase IV studies to meet post-marketing requirements/commitments
7 Median Survival Age of CF Patients < Year Source: Cystic Fibrosis Foundation, National Patient Registry
8 Research Investments are Critical to Advance Science and Targets Number of Articles Published Number of Articles Published Number of Articles Published Cystic Fibrosis Publications in Medical/Scientific Journals Research Development Program established CF basic defect described CF gene (CFTR) cloned 1990 s - CFTR biology advances rapidly 2000 s Research consortia formed (Manhattan like projects) Year Year
9 Scientific Discoveries Link CFTR Function and Lung Pathophysiology Cl -, Na +, H 2 0 Normal Airway Mucus layer moves bacteria, viruses and particles out of the airway CFTR Protein Cl -, Na +, H 2 0 CF Airway Mucus accumulates Blocks small airway Traps bacteria Inflammation Bronchiectasis Mucus Plug in Airway Robinson & Bye. Pediatr Pulmonol 2002;33:
10 Therapeutics Era Begins in 1990s Pulmozyme approved 1994 TOBI approved 1997 These therapies address CF symptoms Despite significant advances in understanding CFTR, translational efforts that target basic defect were lacking
11 CF Foundation Begins Therapeutic Development Program (TDP) in 1999 Designed to attract industry partners to focus on CFTR as a target Components of TDP Financial assistance Research tools Scientific advisory committee Therapeutic development network TDP model now used by many disease foundations Favorably reviewed by Harvard Business Review
12 Therapeutics Development Network (TDN) Established in 1998 to ensure safe and efficient performance of CF clinical trials 77 clinical trial sites Coordinating center Biostatistical unit Independent data safety monitoring board
13 Competencies Required for CF Trials sweat chloride testing membrane physiology microbiology cytology inflammatory markers infant pulmonary function diagnostic imaging biostatistics trial design/logistics
14 The TDN has completed 70 clinical trials, enrolling over 9000 subjects
15 CFF- funded Vertex Program An example of putting scientific advances, TDP and TDN to work
16 Therapeutic Approaches by Class F508del CFTR Processing Corrector CFTR Potentiators Rowe SM, et al., New Engl J Med 352(19): , 2005 Translational Readthrough
17 Vertex Program Goals Orally bioavailable drugs Two CFTR targets: Potentiators: Increase opening (gating) of CFTR channels Correctors: Increase number and function of CFTR channels at the cell surface Cl- VX-770 Cl- Cl- ClCl- Cl- Cl- Cl- ClCl- G551D Cl- Cl- VX-809 Cl- F508del Cl- Cl- ClCl-
18 High-Throughput Screening >10,000 Primary Assays/day
19 Untreated VX-770 Untreated CFTR Activity (% wt-cftr) Potentiator VX-770 Increases G551D CFTR Activity to 50% of Normal in the Laboratory 120 G551D/F508del-HBE Wild-type-HBE (normal) We think 10-25% may be enough to see clinical benefit 0
20 Ivacaftor Phase 3 Results in CF Patients with G551D Mutation No safety concerns 16% relative improvement in lung function 55% less likely to have pulmonary exacerbation Weight gain of seven pounds over 48 weeks Patients felt significantly better Sweat chloride dropped below diagnostic level N Engl J Med 2011; 365:
21 Change in sweat chloride concentration mmol/l (mean, 95% CI) Change from Baseline in Sweat Chloride with Ivacaftor Placebo Ivacaftor Treatment effect through Week mmol/l P < Treatment effect through Week mmol/l P < Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48 Estimates are model-based. Points and 95% CI are unadjusted (raw) Key secondary endpoint in gold
22 Ramsey et al 2011 Lung Function Improves with Ivacaftor
23 Ramsey et al 2011 Lung Function Improvement By Rx
24 FDA Approves Ivacaftor Drug Information Association
25 Two Year Ivacaftor Lung Function Results
26 CF Foundation Begins GOAL Study Visit 1 Decision made to start ivacaftor? (before end of study enrollment) yes no Visit 2 Day 1 Visit 3 Visit 4 Visit 5 Pre- Dose First dose of ivacaftor ivacaftor not prescribed 1 month after Day 1 3 months after Day 1 6 months after Day 1 Visit 1b Core Study Measures Additional Sub-Study Measures Clinical outcome Sweat chloride Quality of life CFQ-R SNOT-20 CFRSD Biomarker collection Serum Plasma DNA Urine Sputum MCC/Rheology visits 2,3,4 Radionuclear mucociliary clearance Micro-rheology Bulk rheology Intestinal ph visits 2, 3 Intestinal ph by radiofrequency transmitter Sweat Rate visits 1 to 4 Sweat evaporimetry Exploratory sweat outcomes Sputum Inflammation & Microbiome visits 2, 5 Induced sputum Inflammatory mediators Sputum microbiome
27 Expanding the Benefit of Ivacaftor Ivacaftor Could Help These Mutational Classes Trials started 15% or more of patients may benefit Rowe SM, et al., NEJM 2005;352(19):
28 What about the most common mutation - F508del?
29 VX-809 Corrector & Ivacaftor Potentiator Effect on F508del CFTR Activity Cl- ClCl- VX-770: Increases channel opening of corrected F508del-CFTR ClCl- Cl- ClCl- Cl- Cl- Cl- ClCl- ClCl- Cl Corrector + VX-770 Cl- 30 Corrector Cl- 40 Untreated Corrector: Increases cell surface density and function of F508del-CFTR Activity F508del-CFTRActivity F508-CFTR (% wild-type CFTR) F508del-HBE F508-HBE
30 VX 809/Ivacaftor FEV1 Results VX mg once-daily in F508del homozygous patients VX mg qd or placebo VX mg qd + ivacaftor 250mg q12h or placebo Mean absolute change from baseline in percent of predicted FEV1 Treatment effect = effect of active therapy minus effect of placebo NS, not significant; qd, once-daily; q12h, every 12 hours Vertex Press Release, June 28, Treatment effect (Day 0 28) 2.0 points P = 0.36 Active treatment Placebo Day 0 Day 28 Day 56 Study day Treatment effect (Day 28 56) points P < 0.001
31 VX-809/Ivacaftor Phase 2 Results VX-809 well tolerated in combination with ivacaftor FEV1 improved 8.6% as compared to placebo (p= 0.001) in highest dose homozygous combination group Results support Phase 3 trials Homozygous F508del patients, n= 1000, 6 month duration, followed by open label extension Trials starting this month
32 Percent of Population CFTR Modulation Expansion % % 65% VX809/Kalydeco (F508/0ther) VX809/Kalydeco (F508/F508) Kalydeco % 15% 4% Year Available To Patients
33 Discovery/Screening Review Post-marketing New Drug Development Pre-IND Synthesis and Purification Phase 1 20% Pre-IND Success Rate 50% Clinical Studies Success Rate Phase 2 Phase 3 NDA 80% Success Rate Animal Testing Short-term Long-term Avg: 5-7 yrs Avg: 6-7 yrs Avg: 1 yr Standard Avg: 6 mo Priority
34 Second Generation CFTR Screening Program Pharma and Biotech Partnerships in place CFF Consortia have developed many of the high throughput discovery screens being used All programs have scientific advisory boards Targets are F508 and stop codon mutations Ultimate goal is to effectively treat 100% of patients
35 Challenges in Developing Therapies for Orphan Diseases Identifying, characterizing, and reaching very small target populations CF Care Center Network CF Patient Registry Identifying biologically relevant targets Research grants Research Development Program Research consortia Developing clinical trial tools Clinical Research Network (TDN) Outcome measures (SOPs and core labs) Biostatistical Unit and TDN expertise for trial design Drug discovery Therapeutic Development Program Forcing collaboration between academia and industry
36
37 % Predicted Lung Function The Benefits of New Therapies Age (years)
38 Thank you!
Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs
Transformational Treatments PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Symptom-based CF Therapies 45 Median Predicted Survival Age of US Patients with Cystic Fibrosis 41
More informationCystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
More informationA Genetic Approach to the Treatment of Cystic Fibrosis
A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller, PhD Chief Scientific Officer and Executive Vice President Global Research and Development Vertex Pharmaceuticals, Incorporated March
More informationCystic Fibrosis Foundation Patient Registry 2013
5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical
More informationThe Future of CF Therapy
The Future of CF Therapy Peter J. Mogayzel, Jr., M.D., Ph.D. Eudowood Division of Pediatric Respiratory Sciences The Johns Hopkins School of Medicine Overview The Future of CF Therapy Personalized therapy
More informationPharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there
More informationCF: Understanding the Biology Curing the Disease
CF: Understanding the Biology Curing the Disease Scott H. Donaldson, MD Associate Professor of Medicine Director, Adult CF Care Center University of North Carolina at Chapel Hill Defining the path Drilling
More informationBriefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee
FDA Advisory Committee Briefing Materials Page 1 of 157 Briefing Document FDA Pulmonary - Allergy Drugs Advisory Committee Ivacaftor for the Treatment of Cystic Fibrosis in Patients Age 6 Years and Older
More informationPhase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients
Phase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients July 18, 2017 Agenda Introduction Michael Partridge, VP Investor Relations
More information"Management and Treatment of Patients with Cystic fibrosis (CF)
"Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March
More informationPhase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures
Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures in CF Patients March 29, 2017 Agenda Introduction Michael
More informationHOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF
HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF Peter D. Sly MBBS, MD, FRACP, DSc OUTLINE Goals of CF treatment Drivers of early disease neutrophilic inflammation oxidative stress
More informationWe strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis
Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward
More informationCystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moss RB, Flume PA, Elborn JS, et al, on behalf
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationPediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.
Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival
More informationNACFC investor meeting. Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC November 2017 Copyright 2017 Galapagos NV
NACFC investor meeting Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC 2017 2 November 2017 Copyright 2017 Galapagos NV Disclaimer This presentation contains forward-looking statements,
More informationDisclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016
Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy Susanna A McColley, MD Associate Chief Research Officer Stanley Manne Children s Research Institute
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationClinical Trials for Rare Diseases in CDER
Clinical Trials for Rare Diseases in CDER CDER Antibacterial Task Force/CTTI Think Tank October 11, 2012 Kathryn O Connell, MD PhD Medical Officer, Rare Diseases Program Office of New Drugs, CDER, FDA
More informationCost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation
Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation January 2013 1. A rapid review submission on the drug ivacaftor
More informationNorth American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR
More informationGLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1)
GLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1) ECFS, Sevilla, Spain 9 June 2017 Jane Davies on behalf of the SAPHIRA1 Study Team Copyright
More informationPA Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCystic Fibrosis Diagnosis and Treatment
Cystic Fibrosis Diagnosis and Treatment Financial Disclosures Personal financial relationships with commercial interests relevant to medicine, within the past 3 years: NJH site PI for AstraZeneca. As faculty
More informationFrom CF Adult and Family Advisors (AFA) to Community Voice
2016 Year in Review From CF Adult and Family Advisors (AFA) to Community Voice Where we have been and where we are going Community Voice is composed of over 300 people with cystic fibrosis, parents, spouses,
More informationKalydeco. Kalydeco (ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.03 Subject: Kalydeco Page: 1 of 6 Last Review Date: November 30, 2018 Kalydeco Description Kalydeco
More informationOpening Doors to CF Clinical Research: Change is Coming
Opening Doors to CF Clinical Research: Change is Coming Disclosures Contracts with sponsors for clinical trials conducted at UNC-Chapel Hill: CFFT NIH/NHLBI AbbVie Inc. Aptalis Pharma US, Inc. Janssen
More informationBrand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated
Brand Name: Kalydeco Generic: ivacaftor Manufacturer 1 : Vertex Pharmaceuticals Incorporated Drug Class 2,3 : Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator Uses: Labeled Uses 1,2,3,4,5
More informationCystic Fibrosis Care at the University of Florida
Cystic Fibrosis Care at the University of Florida Objectives To introduce you to the University of Florida CF Center To review center specific data for the UF pediatric CF Center To review current status
More informationA Cure for All: Leaving No One Behind. Assuring Effective Therapies for All Patients with Cystic Fibrosis
A Cure for All: Leaving No One Behind Assuring Effective Therapies for All Patients with Cystic Fibrosis Topics for Today s Presentation Demographics of the CF patient population in the modulator era
More informationOral Cystic Fibrosis Modulators
Oral Cystic Fibrosis Modulators Goals: To ensure appropriate drug use and limit to patient populations in which they have demonstrated to be effective and safe. To monitor for clinical response for appropriate
More informationOrkambi. Orkambi (lumacaftor/ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.06 Subject: Orkambi Page: 1 of 6 Last Review Date: November 30, 2018 Orkambi Description Orkambi (lumacaftor/ivacaftor)
More informationOpinion 7 November 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 7 November 2012 KALYDECO 150 mg film-coated tablets B/56 (CIP code: 34009 266 060 5 3) Applicant: VERTEX INN ATC Code
More informationNorth American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR
More informationCavosonstat Phase 2 Trial Results. November 28 th, 2016
Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David
More informationPediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives
Nationwide Newborn Screening for Cystic Fibrosis: Finally Creating an Opportunity for All Patients to Have Better Outcomes Philip M Farrell, MD, PhD* University of Wisconsin-Madison *No disclosures other
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 5 November 2014 KALYDECO 150 mg, film-coated tablet B/56 (CIP: 34009 266 060 5 3) Applicant: VERTEX INN ATC code Reason
More informationEngaging with FDA: A Guide for Foundation Funders of Research. FasterCures Webinar Series presents. April 18, 2012
FasterCures Webinar Series presents Engaging with FDA: A Guide for Foundation Funders of Research April 18, 2012 Moderated by Margaret Anderson Executive Director, FasterCures Engaging with FDA: A Guide
More informationPulmonary Exacerbations:
Pulmonary Exacerbations: Better Understanding Needed Michael Tracy, MD Clinical Assistant Professor Pediatric Pulmonary CF Pulmonary Exacerbations Definition Importance Causes Treatment Research opportunities
More informationRecently, the cystic fibrosis (CF) community celebrated the 25th
focused review A new era of personalized medicine for cystic fibrosis at last! Bradley S Quon MD MSc FRCPC 1,2, Pearce G Wilcox MD FRCPC 1,2 BS Quon, PG Wilcox. A new era of personalized medicine for cystic
More informationWhat is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
More informationSummary A pharmaceutical company which develops therapeutic products for
Innovative products for respiratory diseases Annual General Meeting October 2012 Pharmaxis - company overview Summary A pharmaceutical company which develops therapeutic products for human chronic respiratory
More informationClinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)
Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations) Reference: NHS England: A01/P/c NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Cystic Fibrosis Agents (Kalydeco, Orkambi ) Rx.01.117 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
More informationRespiratory Pharmacology: Treatment of Cystic Fibrosis
Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationEvaluation of Patients with Diffuse Bronchiectasis
Evaluation of Patients with Diffuse Bronchiectasis Dr. Patricia Eshaghian, MD Assistant Clinical Professor of Medicine Director, UCLA Adult Cystic Fibrosis Affiliate Program UCLA Division of Pulmonary
More informationCystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus
Eur Respir Rev 2013; 22: 127, 66 71 DOI: 10.1183/09059180.00008512 CopyrightßERS 2013 REVIEW Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Isabelle Sermet-Gaudelus ABSTRACT:
More informationEFFECT OF FOUR SETS OF DISTINCT MODULATORS ON NON-F508DEL MUTATIONS THAT CAUSE CYSTIC FIBROSIS
EFFECT OF FOUR SETS OF DISTINCT MODULATORS ON NON-F508DEL MUTATIONS THAT CAUSE CYSTIC FIBROSIS BHATT, PRIYANKA; BAILEY, VIOLAINE; DASGUPTA, AFIA; CHIN, JUSTIN; AN, WEILING; BRESILLA, CASTERA; KWOK, IRIS;
More informationSymdeko. Symdeko (tezacaftor and ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.10 Subject: Symdeko Page: 1 of 5 Last Review Date: June 22, 2018 Symdeko Description Symdeko (tezacaftor
More informationYou Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM
You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative
More informationCase Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?
Names: Date: Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis? Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the
More informationA Case of Cystic Fibrosis
Name(s) Date A Case of Cystic Fibrosis Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the day. The baby's parents had brought young Zoey to the emergency
More informationCystic Fibrosis Update
Cystic Fibrosis Update More than Decades of Discovery Dr. Raj Padman Professor of Pediatric TJU Board certified in Pediatrics, Pulmonology, and Sleep Medicine Dupont, Kosciusko Community, Lutheran, Rehabilitation,
More informationInnovative products for r espiratory rrespiratory d iseases diseases September 2012
Innovative products for respiratory diseases September 2012 Pharmaxis - company overview Summary A pharmaceutical company which develops therapeutic products for human chronic respiratory diseases. Headquartered
More informationA Quick Guide to the. I507del. Mutation CFTR SCIENCE
A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum
More informationClass Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClass Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationBTIG LLC Dane Leone, CFA (212) Source: SAPHIRA 1 Results (December 20th 2016), Ph2a open label trial of GLPG1837
Pre-clinical assay outcomes at Vertex have proven to be reliable markers for in vivo results, we expect the same from Galapagos: Outcomes from the EVOLVE and EXPAND studies have set a new bar for clinical
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationMolecular Basis of Personalized Therapies for CF: Can We Treat All Patients?
CF Europe Meeting Molecular Basis of Personalized Therapies for CF: Can We Treat All Patients? Margarida D Amaral Brussels, 13 June 2015 The CF Pathogenesis Cascade 2 Defective CF Genes Deficient CFTR
More informationCYSTIC FIBROSIS CANADA S CF PHYSICIAN PANEL ON LUMACAFTOR/IVACAFTOR: RECOMMENDATIONS FOR CRITERIA FOR CLINICAL USE
CYSTIC FIBROSIS CANADA S CF PHYSICIAN PANEL ON LUMACAFTOR/IVACAFTOR: RECOMMENDATIONS FOR CRITERIA FOR CLINICAL USE I - INTRODUCTION a) Cystic Fibrosis Cystic fibrosis (CF) is the most common fatal genetic
More informationCystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
More informationTargeted therapies to improve CFTR function in cystic fibrosis
Brodlie et al. Genome Medicine (2015) 7:101 DOI 10.1186/s13073-015-0223-6 REVIEW Targeted therapies to improve CFTR function in cystic fibrosis Malcolm Brodlie 1*, Iram J. Haq 2, Katie Roberts 2 and J.
More informationPediatric Safety Surveillance Workshop
Pediatric Safety Surveillance Workshop Pediatric Safety: Better Surveillance for Children Dianne Murphy, MD, FAAP Office of Pediatric Therapeutics Office of the Commissioner, FDA September 13-14 th, 2010
More informationCYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION LUMACAFTOR / IVACAFTOR (Orkambi Vertex Pharmaceuticals [Canada] Inc.) Indication: Cystic Fibrosis, F508del-CFTR mutation Recommendation: The CADTH
More informationNew Drug Evaluation: Lumacaftor/Ivacaftor
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
More informationIVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER
IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER February 21, 2014 U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in Eight
More informationThe Deciphering Development Disorders (DDD) project: What a genomic approach can achieve
The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5 TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationDisclosures. Learning Objectives. What is Cystic Fibrosis? Background
39 th National Conference on Pediatric Health Care March 19-22, 2018 CHICAGO Disclosures The Vision and the Journey of Cystic Fibrosis: Newborn Screening to Breakthrough Therapy March 20, 2018 Cynthia
More informationHIT-CF New clinical trial design in Cystic Fibrosis
HIT-CF New clinical trial design in Cystic Fibrosis Peter van Mourik, MD, PhD-student Pediatric Pulmonology, University Medical Center Utrecht, the Netherlands Contents - Difficulties of clinical trials
More informationGoals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy
CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life
Breathtaking science Developing respiratory drugs to improve health and quality of life June 2017 Forward-Looking Statements This presentation contains forward looking statements that are based on the
More informationivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd
ivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd 04 November 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationExploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis
CME/CNE/CPE Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis Course Director Jerry Nick, MD National Jewish Health University of Colorado Denver,
More informationScottish Paediatric Cystic Fibrosis MCN. Protocols / Guidelines. Ivacaftor: A guideline for use in paediatric CF patients in Scotland
Scottish Paediatric Cystic Fibrosis MCN Protocols / Guidelines Ivacaftor: A guideline for use in paediatric CF patients in Scotland Authors: Dr Carol Dryden Dr Jane Wilkinson Miss Julie Crocker, Registered
More informationEstablishing a Culture of Research. Cynthia George, MSN, CRNP Sr. Director Patient Engagement
Establishing a Culture of Research Cynthia George, MSN, CRNP Sr. Director Patient Engagement Cystic Fibrosis Foundation Founded By Parents - 1955 CF Foundation s Mission To cure CF and provide all people
More informationDevelopment of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE) Dr. Juliane Bernholz, Novartis (Coordinator) Dr. Andrea Appenzeller,
More informationANALYST & INVESTOR EVENT NACFC 2016, Orlando, Florida
ANALYST & INVESTOR EVENT NACFC 216, Orlando, Florida Date: October 27th, 216 Presenters: Daniel de Boer, Noreen Henig and JP Clancy Agenda Overview and introduction by Daniel de Boer The relevance of the
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationAdvances in CF therapies and their effect on GI manifestations. Presenter Disclosure Daniel Gelfond, MD Relationship related to this presentation
Advances in CF therapies and their effect on GI manifestations Daniel Gelfond, MD University of Rochester WNY Pediatric Gastroenterology Presenter Disclosure Daniel Gelfond, MD Relationship related to
More informationLumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
601934TAR0010.1177/1753465815601934Therapeutic Advances in Respiratory DiseaseKuk and Taylor-Cousar research-article2015 Therapeutic Advances in Respiratory Disease Review Lumacaftor and ivacaftor in the
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationCystic fibrosis: hitting the target
Cystic fibrosis: hitting the target Heartland Collaborative Annual Meeting Friday, October 5, 2012 Thomas Ferkol MD 1938 1953 Cystic fibrosis: a historical timeline Cystic fibrosis (CF) of the pancreas
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, 2012 ClinicalTrials.gov ID: NCT00457821 Study Identification Unique Protocol ID: VX06-770-101 Brief Title:
More informationCystic Fibrosis: KOL Insight [2017]
Cystic Fibrosis: KOL Insight [2017] Cystic Fibrosis: KOL Insight [2017] BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationAnti-inflammatory Therapy Targets Orphan Lung Disease-June 17
Anti-inflammatory Therapy Targets Orphan Lung Disease-June 17 Disease Modification in Cystic Fibrosis (CF) Targeted Approach in Pulmonary Hypertension (PH) Experienced Management Team Greg Duncan President/CEO
More informationThe Cystic Fibrosis Gene. about. CF is one of the most common genetic diseases that cause death in both children and
Gill1 Peter Gill Malory Klocke Research Paper 02 August, 2011 The Cystic Fibrosis Gene Cystic fibrosis, better known as CF, is a genetic disease most people know very little about. CF is one of the most
More informationForward Looking Statements
Therapeutic products for respiratory diseases September 2008 Forward Looking Statements This presentation may contain forward-looking statements that are based on management s current expectations and
More informationMission statement. CF Parent Advisory Group at AFCH Coming Soon. CF Family Education Day 2017 YOUR CF CLINIC VISIT
University of Wisconsin Clinical Sciences Center Newsletter of the Pediatric and Adult Cystic Fibrosis Centers Spring, 2017 Mission statement Our Cystic Fibrosis Center s mission is to provide excellent
More informationCystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL
Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL Objectives: At the end of the presentation the listeners will Be able to describe neonatal
More information4th International Summer School on Rare Disease and Orphan Drug Registries
4th International Summer School on Rare Disease and Orphan Drug Registries Experiences with building and managing a registry: The Italian Cystic Fibrosis Patients Registry Marco Salvatore, National Center
More informationADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development Wm Z Potter, MD, PhD Sr. Advisor, NIMH IOM, Nov 15, 2014 Disclosures Former employee of Lilly
More information